Pregnancy and Risk of Venous Thromboembolism

Launched by HOSPICES CIVILS DE LYON · Sep 5, 2018

Keywords

ClinConnect Summary

This clinical trial is focused on understanding how to better manage the risk of a condition called venous thromboembolism (VTE) during pregnancy. VTE is a serious condition where blood clots form in the veins, which can be particularly risky for pregnant women. The researchers aim to evaluate a specific tool called the Lyon-VTE-score that helps doctors assess the individual risk of each pregnant woman for developing VTE. By using this score, healthcare providers can tailor treatment plans more effectively, ensuring that women at higher risk receive the right preventive care.

Eligible participants for this study are adult pregnant women who have a personal history of VTE or a condition that increases their risk for blood clots, and who are willing to give their consent to participate. Women who have certain medical complications or contraindications to heparin therapy will not be included. If enrolled, participants can expect to be part of a study that compares the new personalized approach using the Lyon-VTE-score with standard care practices. This innovative strategy aims to improve safety and effectiveness in preventing VTE during pregnancy, providing a more individualized treatment plan for each patient.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult pregnant women at high risk of VTE (with a personal history of VTE and/or thrombophilia)
• • giving informed consent to participate to the study
• Exclusion Criteria:
• • contraindication to heparin therapy,
• • women with obstetrical complications only, with no history of VTE (pre-eclampsia, HELLP\[ Hemolysis, Elevated Liver enzymes, Low Platelet count\],intra-uterine growth retardation, miscarriage, etc),
• • patients with a history of superficial venous thrombosis, and those with the highest VTE risk for whom clear recommendations with a high level of evidence are available (patients on long-term anticoagulants, or those with antiphospholipid syndrome or antithrombin deficiency).
• • Patient participating in an ongoing study that could interfere with the study,
• • Patient under legal protection measure.